2017 American Transplant Congress
The Natural History of Kidney Rejection: How Do Molecular Disease States Change Over Time in Patients with Repeat Indication Biopsies?
University of Alberta, Edmonton, AB, Canada
Molecular phenotypes are highly reproducible, but how do they evolve over time? In an unsupervised microarray analysis, 1208 kidney transplant biopsies were assigned to one…2017 American Transplant Congress
Early and Late Antibody Mediated Rejection and Mixed Acute Rejection Are Clinically Distinct and Demonstrate Biologic Differences in Immunodominant Donor Specific Antibody Characteristics.
1U of Cincinnati, Cincinnati; 2The Christ Hospital, Cincinnati
Early and late antibody mediated rejection (AMR) and mixed acute rejection (MAR) possibly result from fundamentally different immunologic processes. DSA mediates direct injury by complement-dependent…2017 American Transplant Congress
Early Antibody-Mediated Rejection C4d Status Remains a Marker of Prognosis in HLA-Incompatible Kidney Transplantation.
1CHP, Porto, Portugal; 2IPST, Porto, Portugal
Banff criteria for the diagnosis of antibody-mediated rejection (AMR) in kidney transplantation (KT) was recently updated to include the entity of C4d negative AMR, if…2017 American Transplant Congress
Human Transitional B Cell Cytokine Profile Predicts Renal Allograft Rejection and Clinical Course.
In Kidney Transplant Recipients (KTRs), non-invasive predictive biomarkers that allow early intervention are limited. Here we report findings from a prospective longitudinal study using B…2017 American Transplant Congress
Apoptotic Exosome-Like Vesicles Released During Tissue Injury Trigger IL23/IL-17 Autoimmune Axis and Accelerate Rejection.
Autoantibodies to apoptotic antigens, such as perlecan/LG3, are present pre-transplantation and contribute to organ rejection. We previously showed that during tissue injury, apoptotic endothelial cells…2017 American Transplant Congress
Donor-Derived Cell-Free DNA Is a Dynamic Biomarker of Active Rejection in Kidney Allografts.
Purpose: Donor-derived cell-free DNA (dd-cfDNA) has shown promise as a biomarker in identification of allograft rejection. Here we report on the changes in dd-cfDNA prior…2017 American Transplant Congress
Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy.
The need for using induction therapy in de novo non-HLA sensitized kidney-transplant patients receiving tacrolimus-based therapy is a matter of debate. The aims of this…2017 American Transplant Congress
Antibody Mediated Rejection and Donor Specific Antibodies in Heart Transplant Patients: Single Center Experience.
BACKGROUND AND AIMS: Preexisting donor specific antibodies (DSA) cause acute antibody mediated rejection (AMR), which can be avoided during pre-transplant work up. Diagnosis and management…2017 American Transplant Congress
Novel Biomarkers for Segregating Lung Transplant Rejection Phenotypes.
We sought to investigate biomarkers in BAL fluid and tissue for segregating BOS and RAS chronic rejection phenotypes in lung allografts. We had previously identified…2017 American Transplant Congress
Integrated Magnetic-Electrochemical Exosome (iMEX) Technology to Detect Rejection in Kidney Transplant Recipients.
Transplantation Research Center, Harvard Medical School, Boston; Exosome Diagnostic Inc, Cambridge
Methods for monitoring clinical rejection including increases in serum creatinine and urinary protein excretion may not reflect subclinical rejection. Similarly repeat biopsy may result in…
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 172
- Next Page »